The reported risk of FN with AC chemotherapy regimen is 10%-20%. The current study is designed to study the incidence and effects of FN in localized breast cancer patients receiving AC regimen as a component of adjuvant or neoadjuvant chemotherapy.
Introduction
Breast cancer is the most common cancer in India and the second most common in the world, both sexes combined. [1] Over the past few decades, advances in adjuvant chemotherapy of the breast resulted in decline in mortality due to breast cancer. Sequential anthracycline followed by taxane-based regimen remains to be the gold standard when adjuvant chemotherapy is indicated in majority of cases. Doxorubicin and cyclophosphamide (AC) is the widely accepted regimen; however, it carries the potential risk of myelosuppression, leading to febrile neutropenia (FN). The efficacy of the adjuvant chemotherapy is determined by the dose density and intensity of chemotherapeutic agents, apart from other factors. [2] FN is a serious complication, and the effects are multitude. It has the potential to cause significant morbidity to a patient, apprehension to the caretakers, economic burden to the society, and increased workload to the health-care providers, especially in resource-limited setting. Furthermore, if the patient is suffering from significant comorbidities that increase the risk of infection, it can increase mortality compromising survival. [3] FN may adversely affect the treatment outcomes as it may lead to treatment interruption, dose reductions, and even termination of chemotherapy. The cost incurred due to the hospitalization and the use of antibiotics is also significant. [4] Hence, it is important to take necessary precautions to prevent the occurrence of FN by the use of primary prophylaxis with granulocyte colony-stimulating factor (G-CSF).
On the other hand, there are problems associated with the routine use of the G-CSF which include adverse reactions and cost of the G-CSF. [5] Hence, sagacious use of G-CSF as primary prophylaxis is advised. The current recommendations guide to use primary prophylaxis with G-CSF if the risk of developing FN due to chemotherapy is >20%. [6] How to cite this article: Palukuri NR, Yedla RP, Bala SC, Kuruva SP, Chennamaneni R, Konatam ML, et al. Incidence of febrile neutropenia with commonly used chemotherapy regimen in localized breast cancer. South Asian J Cancer 2020;9:4-6.
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Statistical methods
Descriptive statistics were used to describe patient demographics, disease characteristics, chemotherapy details, and FN details. Univariate analysis was used to find association between FN and several variables.
Results
Demographic data and disease characteristics
A total of 231 patients between 2013 and 2017 who met the eligibility criteria were analyzed. All the patients were females (100%). Patient characteristics are shown in Table 1 . A total of 912 cycles of chemotherapy were administered. Two hundred and twenty-five (97.8%) patients completed all four cycles of planned AC chemotherapy. Two patients defaulted after one cycle and three patients after two cycles due to reasons other than FN.
Febrile neutropenia characteristics
A total of 14 (6.1%) patients developed at least one episode of FN. Overall, 16 episodes of FN were observed as two patients suffered from FN twice. Of 225 and six patients with Eastern Co-operative Oncology Group (ECOG) performance status (PS) of ≤1 and ≥2, 11 (4.8%) and 3 (50%) patients developed FN, respectively. The incidence of FN episodes after cycle 1, 2, 3, and 4 were 10 (4.3%), 3 (1.3%), 2 (0.9%), and 1 (0.4%), respectively. The median day of onset of FN was 12 (range, day [8] [9] [10] [11] [12] [13] [14] [15] . The median day of recovery of FN was 16 (range, day 12-19). All the patients were managed on in-patient basis. Blood cultures done were sterile in all patients, and imaging done did not reveal any source of probable infection. All the patients were managed with intravenous antibiotics and G-CSF. There were no deaths due to FN and the median duration of hospital stay was 4 days (range, 2-8 days).
Impact of febrile neutropenia on chemotherapy delivery
None of the patients had either treatment delay or chemotherapy dose reduction due to FN.
Factors affecting febrile neutropenia
Age, height, weight, body mass index (BMI), body surface area, comorbidities, menopausal status, AJCC staging, and ECOG PS were analyzed using univariate analysis. None of them were found to be statistically significant in causing FN, except for the ECOG PS of ≥2 (P = 0.0001).
Discussion
Anthracycline and cyclophosphamide chemotherapy is generally well tolerated but, sometimes, may lead to serious and life-threatening complications including FN. The present study is a single-institutional, retrospective study which evaluated the incidence and risk factors associated with FN and its effects such as length of hospitalization, dose reduction, and treatment delay in patients with localized breast cancer treated with AC chemotherapy as part of their neoadjuvant or adjuvant chemotherapy. We believed that this study provides an informative insight into the supportive care management of the most common chemotherapy regimen used in the most common malignancy in India.
In the present study, the incidence of FN is only 6.1%, and hence, AC chemotherapy falls into low-risk category. The incidence of FN with AC chemotherapy in multi-institutional randomized controlled trials (RCTs) [8] [9] [10] and retrospective studies [7, [11] [12] [13] ranged from 0.3% to 6% and 6.1% to 25.2%, respectively. Risk of FN is more in retrospective studies compared to the RCTs, the possible reason being the stringent eligibility criteria for entry into RCTs. However, in the real-world scenario, a clinician would see much more incidence of FN, which is supported by the retrospective studies. Hence, we compared the present study with other retrospective studies. In the study by Kim et al., [12] FN is exceptionally higher for reasons unclear.
The present study shows that the risk of FN is less compared to other single-institutional studies. The possible explanation for this would be the differences in the demographic characteristics of the patients across various studies that have bearing on the risk of FN. Ethnic differences in hematologic toxicities which were reported for lung cancer may also have contributed for this difference in the incidence of FN. [14] Polymorphism of the hepatic enzymes involved in the metabolism of AC was also described in the literature. [15] Factors that predispose to FN include type of chemotherapy, depth and duration of neutropenia, relative dose density, previous chemotherapy and radiotherapy, advanced age, female gender, poor PS, poor nutritional status, and presence of other comorbid conditions. [16] In the present study, the only variable that was significantly associated with the elevated risk of FN was ECOG PS. Kim et al. [12] reported that BMI was associated with increased risk of FN.
Maintaining relative dose intensity of >85% is of paramount importance to retain the optimal efficacy offered by the adjuvant chemotherapy. [2] There was no chemotherapy dose reduction or treatment delay in our study, whereas only a minority of patients had dose reduction and treatment delays due to FN in other studies. Dose reduction and dose delay in various studies ranged from 0% to 16.5% and 0% to 19.5%, respectively. [7, 11, 12] Patients who develop FN may be treated without dose reduction and delay in subsequent cycles provided that the diagnosis of FN is prompt and facilities for timely intervention with adequate supportive measures are available.
The present study has certain limitations. This was a retrospective study; however, necessary measures were taken to ensure that findings were accurate. The sample size is small but is hypothesis generating. This study was unable to correlate with any of the risk factors reported in the literature that makes patients susceptible to FN, except for ECOG PS. This highlights the importance of studies which evaluates risk factors of FN for each cancer type. 
Conclusion
The incidence of FN with AC chemotherapy in breast cancer patients is relatively less in the present study. Routine primary prophylaxis is not recommended as this chemotherapy falls into low-risk category for FN but can be considered for patients with ECOG PS >1. If the diagnosis of FN and institution of appropriate measures are prompt, FN did not affect the delivery of chemotherapy and thus compromise survival.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
Letter to the Editor
An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast-ovarian cancer syndrome DOI: 10.4103/sajc.sajc_157_19
Dear Editor, Poly (ADP-ribose) polymerase inhibitors (PARPi) have demonstrated impressive efficacy in BRCA-mutated gynecological malignancies. [1, 2] Several lines of evidence now support that the DNA Damage repair (DDR)-deficient populations that benefit from PARPi go far beyond BRCA deficiency. Non-small cell lung cancer (NSCLC), the most common cause of death due to cancer worldwide, displays frequent DDR defects, the most frequent being ERCC1. This defect leads to platinum and PARPi sensitivity. Beyond ERCC1, DDR defects leading to platinum sensitivity widely overlap with those underlying PARPi sensitivity. [3, 4] Here, we report a case of 47-year-old doctor with no known comorbidites and family history of ovarian cancer in mother at 63 years and unknown primary squamous cell carcinoma with submandibular lymph node (LN) in sister at 42 years of age. He had hoarseness of voice in December 2016 which was evaluated to have squamous cell carcinoma lung with metastatic paratracheal and aortopulmonary LN after radical treatment with definitive radiotherapy of 59.6 Gy/28# with 6# weekly paclitaxel + carboplatin completed on January 26, 2017, followed by adjuvant 6 cycles of gemcitabine and cisplatin till May 20, 2017. He developed 1.5 cm × 1.2 cm enhancing lesion in the right posterior parietal lesion within 1 month of completion of therapy. He was treated with gamma knife (June 30, 2017) 25 gy for the brain metastasis which recurred with the size of 5 cm × 5.4 cm × 4 cm along with new cervical LN and soft tissue deposit in trapezius in January 2018. Excision of brain metastasis and whole-genome sequencing was performed on a biopsy from a metastasis and blood which revealed deleterious gene mutation in exon 2 of breast cancer 1 (BRCA1) (c.68_69delAG, p.Glu23ValfsTer17) confirming risk of hereditary breast and ovarian cancer syndrome (dated February 4, 2018 MedGenome Labs Private Ltd, Bengaluru, India and ACTREC Genetic Lab, Kharghar). He was then started on olaparib 300 mg twice daily from 10 th February and response positron emission tomography-computed tomography suggest resolution in the lesion in R occipital lesion, mass deposit in trapezius and bilateral cervical Lymph node. On follow up he had sustained response till January 2019 when he developed oligometastatic right supraclavicular LN recurrence which was treated again with radical chemotherapy with cisplatin and definitive radiation to supraclavicular fossa with
